Evidence map›Paper›PMID 40720048›Full record

ArticleDrug delivery and translational research2026

Sunitinib-eluting thin films for Inhibition of corneal neovascularization.

Kunal S Parikh, Jin Yang, Zheng Ding, Richard Shi, Sagun Poudel, Yumin Oh, Lixia Luo, Shiyu Xia, Gregg Duncan, Charles Eberhart and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Emerging ophthalmic drug delivery.Drug delivery and translational research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kunal S Parikh *Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Jin Yang *Center for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Zheng DingCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Richard ShiDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.
Sagun PoudelDepartments of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA.
Yumin OhCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Lixia LuoCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Shiyu XiaCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Gregg DuncanCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Charles EberhartDepartment of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Laura M EnsignCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Justin HanesCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Qingguo XuCenter for Nanomedicine, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA. qxu@vcu.edu.ORCID http://orcid.org/0000-0003-3191-0771

Funding

New method to treat or prevent corneal graft rejectionR01EY027827 · NEI · VIRGINIA COMMONWEALTH UNIVERSITY · PI XU, QINGGUO · 2017 to 2021
$2.0M
NEI NIH HHS R01 EY027827NEI NIH HHS R01EY027827
6 · The paper itself

Abstract

Corneal disease is a leading cause of blindness globally, and is commonly associated with corneal neovascularization, which results in the loss of optical clarity and visual impairment. A wide variety of factors contribute to abnormal growth of new blood vessels into the cornea, including contact lens wear, infectious keratitis, corneal graft rejection, inflammatory disorders and trauma. In each case, proangiogenic factors such as vascular endothelial, platelet-derived, and fibroblast growth factors fuel new blood vessel growth and proliferation. Topical corticosteroids are a front-line treatment for corneal neovascularization, but require patient compliance and long-term use, which can limit efficacy and lead to increased intraocular pressure or cataract development, respectively. There is a need for a simple, effective treatment for corneal neovascularization that improves access and alleviates compliance issues. Here, biodegradable, sunitinib-loaded, nano- and micro-structured thin films were manufactured via electrospinning and applied topically in a rat model of corneal neovascularization. Thin films were characterized for morphology, mechanical and physicochemical properties, and drug release prior to in vivo assessment of biocompatibility and efficacy. Nano-structured thin films demonstrated sustained in vitro release of sunitinib for 30 days, provided sufficient strength for extended topical application, and were biocompatible on rat eyes. Importantly, sunitinib-loaded thin films inhibited corneal neovascularization more significantly than 3x daily sunitinib eye drops, as evidenced by greater reductions in vessel area, length, and vascular endothelial growth factor expression. This sustained drug-delivery platform has potential to provide a safe and effective treatment for ocular surface and corneal disorders.

Indexed as

Angiogenesis InhibitorsCorneal NeovascularizationSunitinibAnimalsDelayed-Action PreparationsDrug LiberationMaleRatsAngiogenesis InhibitorsDelayed-Action PreparationsSunitinibCorneal neovascularizationElectrospinningNanofiberOcular drug deliverySunitinibTyrosine kinase inhibitor

Identifiers

PMID40720048
PMCPMC12777655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.